Travere Therapeutics Inc (TVTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $63.23 (-2.33%), Market cap $3.96B, 52-week low–high $14.09 ~ $44.91.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which ha
Financial statements, price targets, institutional (13F) holdings and related news for Travere Therapeutics Inc are updated in real time on BlackAll Trade.
Travere Therapeutics Inc trades at $63.23 (-2.33%). Real-time quotes and charts are available on BlackAll Trade.
Travere Therapeutics Inc has a market cap of about $3.96B.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's produ